Abstract
Resmetirom is an oral, liver-directed, thyroid hormone receptor beta (THR-β) selective agonist in Phase III development for nonalcoholic steatohepatitis with significant fibrosis (NASH). An economic evaluation was conducted to assess the cost-effectiveness of resmetirom in the US setting.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
